NCT02690350 is a Phase 1 clinical trial of U3-1784 in Advanced Solid Tumors, sponsored by Daiichi Sankyo.

Who is sponsoring NCT02690350?

NCT02690350 is sponsored by Daiichi Sankyo.

What drugs are being tested in NCT02690350?

Interventions in NCT02690350: U3-1784.

What condition does NCT02690350 study?

NCT02690350 studies Advanced Solid Tumors, Hepatocellular Cancer (HCC).

Is NCT02690350 still recruiting?

NCT02690350 is currently terminated. Last updated 16 May 2018.

Last reviewed 2018-05-16 · How we verify

NCT02690350

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open Study Assessing the Safety and Tolerability of U3-1784

Terminated Phase 1 Last updated 16 May 2018

What this trial tests

Phase 1 trial testing U3-1784 in Advanced Solid Tumors in 10 participants. Terminated before completion.

Timeline

29 February 2016

Primary endpoint
28 February 2017

28 February 2017

Quick facts

Lead sponsor	Daiichi Sankyo
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	29 February 2016
Primary completion	28 February 2017
Estimated completion	28 February 2017
Sites	4 locations across United Kingdom

Drugs / interventions tested

U3-1784 — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Hepatocellular Cancer (HCC) — all drugs for Hepatocellular Cancer (HCC) →

Sponsor

Daiichi Sankyo — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors or Hepatocellular Cancer (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of the trial are: * To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours * To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

FGF19-<i>FGFR4</i> Signaling in Hepatocellular Carcinoma.
Raja A, Park I, Haq F, Ahn SM. · · 2019 · cited 111× · PMID 31167419 · DOI 10.3390/cells8060536
FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R, Carneiro BA, Taxter T, Tavora FA, et al · · 2016 · cited 107× · PMID 27409839 · DOI 10.18632/oncotarget.10482
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L, Teng Y. · · 2019 · cited 68× · PMID 30634399 · DOI 10.3390/cells8010031
Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody.
Filocamo G, Buccarelli M, Lahm A, Brunetti M, et al · · 2026 · PMID 41681889 · DOI 10.3390/cancers18030418
Unraveling the FGFR-RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose.
Xian X, Gong R, Rong S, Zhang Z, et al · · 2026 · PMID 41584352 · DOI 10.1016/j.apsb.2025.11.031
FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.
Xu J, Sun P, Zhu W, Liu X, et al · · 2026 · PMID 41328353 · DOI 10.7150/thno.121601

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Daiichi Sankyo trials

Trials by the same sponsor.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02690350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
Last refreshed: 16 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02690350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing